公开(公告)号：EP1915054A2

公开(公告)日：2008-04-30

申请号：EP06789454.3

申请日：2006-08-04

申请人： Merck & Co., Inc.

发明人： BUTORA, Gabor ,  KOEPLINGER, Kenneth, Alan ,  MACCOSS, Malcolm ,  MCMASTERS, Daniel, R. ,  OLSEN, David, B. ,  YANG, Lihu

IPC分类号： A01N43/04 ,  A01N57/00 ,  A61K31/519

CPC分类号： C07H19/06 ,  C07H19/16

摘要： The present invention provides ribonucleoside 2’,3’-cyclic acetals of structural formula I which are precursors or prodrugs of inhibitors of RNA-dependent RNA viral polymerase. These compounds are precursors of inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as precursors or prodrugs of inhibitors of hepatitis C virus (HCV) NS5B polymerase, as precursors or prodrugs of inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compositions containing such ribonucleoside 2’,3’-cyclic acetals alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the ribonucleoside 2’,3’-cyclic acetals of the present invention.